Login
$EOLS
$6.63 +$0.00 (0.0%) After hours

$EOLS SEC Filings

Filed On Filing
09 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook

04 Sep 2026 Form 4: Moatazedi David, Director

Sold 105,108 shares ($950K)

02 Sep 2026 144
31 Aug 2026 SCHEDULE 13G
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

04 Aug 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau® and Nuceiva® across all Evolus commercial markets

08 Jul 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

12 Jun 2026 EFFECT
12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on three proposals, as further described in the Company’s definitive proxy stateme...

10 Jun 2026 CORRESP
10 Jun 2026 UPLOAD
05 Jun 2026 S-3
04 May 2026 10-Q
04 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

29 Apr 2026 DEFA14A
29 Apr 2026 Proxy statement: annual meeting on June 11, 2026

CEO pay $6.4M, down 8.4% · say-on-pay vote

29 Apr 2026 ARS

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support